Drug intelligence / Profile preview

OC-L + Montanide ISA 51 VG

Development stage: Unknown
Lead developer: SEPPIC
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

OC-L + Montanide ISA 51 VG is a vaccine formulation that combines an antigen (OC-L) with the Montanide ISA 51 VG adjuvant. Montanide ISA 51 VG is a water-in-oil emulsion adjuvant composed of a mineral oil and a mannide monooleate surfactant. This adjuvant creates a depot effect at the injection site, allowing for slow and prolonged release of the antigen, which enhances both cellular and humoral immune responses. It is known to induce strong activation of CD8+ and CD4+ T cells and production of cytokines.

Beyond the preview

Go deeper on OC-L + Montanide ISA 51 VG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OC-L + Montanide ISA 51 VG.

Explore the full profile